With shares of Boeing (NYSE:BA) trading around $103, is BA an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
Boeing is an aerospace company. It focuses primarily on engineering, information technology, research and development, test and evaluation, technology strategy development, environmental remediation management and intellectual property management. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital Corporation. As a leading provider of aerospace products and services to large corporations, including the United States Government, look for Boeing to continue to advance and develop this space and fuel aerial progress.
T = Technicals on the Stock Chart are Strong
Boeing stock has seen a very powerful surge higher over the last several years. The stock is set to test previous all-time high prices so it may need time to battle out these prices. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, Boeing is trading above its rising key averages which signal neutral to bullish price action in the near-term.
Top 5 Industrial Conglomerate Companies To Invest In 2015: LPL Investment Holdings Inc.(LPLA)
LPL Investment Holdings Inc. provides an integrated platform of brokerage and investment advisory services to independent financial advisors and financial advisors at financial institutions in the United States. The company?s brokerage offerings include variable and fixed annuities, mutual funds, general securities, alternative investments, retirement and 529 education savings plans, and fixed income; and insurance offerings comprise personalized advance case design, point-of-sale service, and product support for a range of life, disability, and long-term care products. Its fee-based advisory platforms and support solutions offer access to no-load/load-waived mutual funds, exchange-traded funds, stocks, bonds, conservative option strategies, unit investment trusts and no-load, institutional money managers, and multi-manager variable annuities through five platforms, as well as third-party equity research and asset-management services, and fee-based advisory and consulting services to retirement plans. The company?s cash sweep programs consist of money market sweep vehicles and an insured bank deposit sweep vehicles. Its services also include tools and services that enable advisors to maintain their practice; and trust, investment management oversight, and custodial services for estates and families, as well as technology and open architecture investment management solutions to trust departments of financial institutions. LPL Investment Holdings Inc. provides its services to approximately 12,800 independent financial advisors from a range of firms, including wirehouses, regional and insurance broker dealers, banks, and other independent firms; and registered investment advisors, and advisors at small and mid-sized financial institutions. The company was founded in 1968 and is headquartered in Boston, Massachusetts.
Advisors' Opinion:- [By Ben Levisohn]
Discount brokers had a great 2013, in large part because of the perceived boost they would get from rising interest rates and rising stock prices. Charles Schwab returned 83%, E*Trade Financial (ETFC) surged 119%, TD Ameritrade (AMTD) rose 88%, and LPL Financial (LPLA) finished the year up 69%.
- [By Marc Bastow]
Global investment and financial advisory services holding company LPL Financial Holdings (LPLA) raised its quarterly dividend 26.3% to 24 cents per share, payable March 10 to shareholders of record as of Feb. 24.
LPLA Dividend Yield: 1.81%
Top Rising Companies To Own In Right Now: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Bryan Murphy]
Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.
- [By Nathalie Tadena]
Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).
Top Rising Companies To Own In Right Now: ZIOPHARM Oncology Inc(ZIOP)
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company's clinical programs include Palifosfamide, a DNA cross-linker, which is in a phase III clinical trial for the treatment of metastatic soft tissue sarcoma in the front-line setting. ZIOPHARM is also developing Palifosfamide in combination with etoposide and carboplatin in phase I clinical trial to determine safety for initiating a pivotal, adaptive phase III trial in front-line. In addition, the company, in partnership with Intrexon Corporation, is developing DNA-based therapeutics (synthetic biology) that include two phase 1 clinical-stage product candidates, both of which are DNA IL-12 to be turned on/off by an oral activator ligand. Further, it is developing Indibulin, an oral tubulin binding agent, which is in Phase 1/2 for metastatic breast cancer; and Darinaparsin , a mitochondrial- and hedgehog-targeted agent that is in a solid tumor phase I study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. The company was founded in 2003 and is headquartered in New York City, New York.
Advisors' Opinion:- [By John Udovich]
Biotech in general has been one of the market�� hottest sectors this year thanks to plenty of mostly good news�along with�new IPOs while small cap biotech stocks Delcath Systems (NASDAQ: DCTH), ZIOPHARM Oncology Inc (NASDAQ: ZIOP), Recro Pharma (NASDAQ: REPH), TetraLogic Pharmaceuticals (NASDAQ: TLOG)�and TNI BioTech (OTCMKTS: TNIB) have also produced their share of news�this week or in recent weeks. Just consider the following:
- [By James E. Brumley]
Four months ago, you could barely give your shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) away. The company announced s on Tuesday, March 26th, that its sarcoma drug Palifosfamide had failed to meet its Phase 3 goals. Shares of ZIOP plunged from $5.13 to $1.82 in a mere day, and were trading as low as $1.51 a week and a half later.
Top Rising Companies To Own In Right Now: Spdr Nuveen Barclays Capital Short Term Municipal Bond Etf (SHM)
SPDR Nuveen Barclays Short Term Municipal Bond ETF (the Fund), formerly SPDR Nuveen Barclays Capital Short Term Municipal Bond ETF, correspond generally to the price and yield performance of the Barclays Capital Managed Money Municipal Short Term Index (the Index). The Fund uses a passive management strategy designed to track the Index. The Index tracks publicly traded municipal bonds that cover the United States dollar-denominated, short-term tax exempt bond market, including state and local general obligation bonds, revenue bonds, insured bonds and pre-refunded bonds. The Fund�� investment manager is SSgA Funds Management, Inc. Advisors' Opinion:- [By Todd Rosenbluth]
Fortunately, there are some short-term muni ETFs to choose from. The largest is SPDR Nuveen Barclays Short-Term Muni Bond (SHM). About 65% of the bonds inside have a AA rating, with most of the remaining ones having a AAA rating.
Top Rising Companies To Own In Right Now: James Hardie Industries SE (JHX)
James Hardie Industries plc, together with its subsidiaries, manufactures and sells fiber cement products and systems for interior and exterior building construction applications primarily in the United States, Canada, Australia, New Zealand, the Philippines, and Europe. Its products principally include fiber cement interior linings, exterior siding products, and related accessories products. The company offers fiber cement products with various patterned profiles and surface finishes for a range of applications, including external siding and soffit lining, internal linings, facades, floor and tile underlay, lattice, fencing, decorative columns, flooring, and ceiling applications; and manufactures and sells fiber reinforced concrete pipes. Its products are used in various markets, such as new residential construction, which include single and multi-family housing; manufactured housing that comprise mobile and pre-fabricated homes; repair and remodeling; and various commerc ial and industrial applications, such as stores, warehouses, offices, hotels, motels, schools, libraries, museums, dormitories, hospitals, detention facilities, religious buildings, and gymnasiums. The company markets its fiber cement products and systems under various Hardie brand names, such as HardieBacker; and other brand names, such as Artisan Lap and Artisan Accent Trim by James Hardie, Cemplank and Prevail siding, Scyon, and Stria siding. The company sells its products directly, as well as through distributors, large home center retailers, small to medium size dealer outlets, and specialist distributors to dealers or lumber yards, consumers, builders, real estate developers, and distributor/hardware stores. James Hardie Industries plc was founded in 1888 and is headquartered in Dublin, the Republic of Ireland.
Advisors' Opinion:- [By Ian Sayson]
Exporters dropped. Samsung Electronics slipped 2.9 percent to 1.329 million won in Seoul. Canon Inc., the world�� biggest camera maker, fell 1.1 percent to 3,215 yen in Tokyo. James Hardie Industries SE (JHX), a building materials supplier that gets about 70 percent of sales from the U.S., tumbled 2.8 percent to A$9.37 in Sydney.
Top Rising Companies To Own In Right Now: Lightstream Resources Ltd (LSTMF.PK)
Lightstream Resources Ltd, formerly PetroBakken Energy Ltd., is a Canada-based oil and gas exploration and production company. The Company�� principal operating areas include southeastern Saskatchewan where it targets the Bakken formation and conventional Mississippian reservoirs, central Alberta, where it is focused on the Cardium formation, and north-central Alberta, where it is engaged in exploring for light oil resource plays. In addition, the Company also has land holdings in the Horn River and Montney plays in northeast British Columbia. On December 31, 2012, Petrobank Energy and Resources Ltd. and PetroBakken Energy Ltd. announced the completion of the reorganization. The Reorganization resulted in a newly incorporated company PetroBakken Energy Ltd. (New PetroBakken). Advisors' Opinion:- [By MLP Trader]
Here are the current top five companies in the list:
CompanySymbolEV/BOEPD/NetbackPrice/NAVEV/DACFPinecrest(PNCGF.PK)53564%4.0XLightstream(LSTMF.PK)131753%4.5XNovus(NOVUF.PK)133290%4.1XZargon(ZARFF.PK)138664%5.6XTwin Butte(TBTEF.PK)155885%5.5XOf the larger companies, one that remains obstinately near the top of the list is Lightstream . Lightstream trades at 40% of its book value and a whopping 13.4% yield.
Top Rising Companies To Own In Right Now: Toyota Motor Corp Ltd Ord(TM)
Toyota Motor Corporation engages in the design, manufacture, assembly, and sale of passenger cars, minivans, and commercial vehicles. It offers conventional engine vehicles, including subcompact and compact cars under the Corolla, Yaris, micropremium iQ, Passo, Ractis, Vitz, and Etios brand names; mini-vehicles, passenger vehicles, commercial vehicles, and auto parts under Toyota brand name; mid-size cars under the Camry, REIZ, Avensis, and Mark X brand names; luxury cars under the Lexus and Crown brands; Century limousine; sports cars under the Scion tC and Lexus brands; sport-utility vehicles under the Sequoia, 4Runner, RAV4, Highlander, FJ Cruiser, and Land Cruiser brands; pickup trucks under the Tacoma and Tundra brands; minivans under the Alphard, Vellfire, Corolla Verso, Wish, Hiace, Regius Ace, Estima, Noah, Voxy, Sienta, Isis, Passo Sette, and the Sienna brands; cabwagons; large, medium, and small trucks; and large, small, and micro-buses. The company also provides hybrid cars under Prius and Crown brands. In addition, it offers a range of financial services comprising retail financing, retail leasing, wholesale financing, and insurance; and credit cards and housing loans. Further, the company designs and manufactures prefabricated housing, as well as involves in the information technology related businesses, such as an e-commerce marketplace known as GAZOO.com; and sales promotions for KDDI communication related products, primarily the au brand. It sells its vehicles in approximately 170 countries and regions, including Japan, North America, Europe, and Asia. The company was founded in 1933 and is headquartered in Toyota City, Japan.
Advisors' Opinion:- [By Chris Isidore]
Mulally has been Ford (F, Fortune 500) CEO since 2006, joining the company from the commercial aircraft unit of Boeing (BA, Fortune 500). He is widely credited with helping Ford avoid bankruptcy and the federal bailout that rivals General Motors (GM, Fortune 500) and Chrysler Group endured in 2009. Under his leadership, Ford recaptured the No. 2 spot in U.S. car sales from Japanese rival Toyota (TM).
No comments:
Post a Comment